Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TKMO SO UNDER VALUED STOCK
By end of December 2023
ASSETS: $3,914,178
REVENUES: $2,691,950
$AVRW: Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$PDGO - Phase I Operation, Inc. has signed a Letter of Intent to utilize the Company to acquire 100% interest in 12 producing oil and gas wells, inclusive of the land where the wells are located, in an all stock transaction. The oil and gas wells are located in Oklahoma.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-And-Gas-Inc-Announces-Change-in-Control-and-Letter-of-Intent?id=425854
$HNRC HNRC CEO Frank Kristan Shares Insights on 2023 Financials, 2024 Outlook, Digital Asset ‘Gold’ Token, and Sponsored SPEC NYSE: HNRA on ‘The Street Reports Podcast’ – Tune In!
https://thestreetreports.com/hnrc-ceo-frank-kristan-shares-insights-on-2023-financials-2024-outlook-digital-asset-gold-token-and-sponsored-spec-nyse-hnra-on-the-street-reports-podcast-tune-in/
$WRIT - WRIT CEO Eric Mitchell stated, We look forward to helping promote this event and supporting our veterans. We anticipate great things to come from this collaboration as we focus on the May 18, 2024, event and future events.
https://www.otcmarkets.com/stock/WRIT/news/WRIT-Media-Group-Inc-Announces-Digital-Marketing-and-Merchandising-Agreement-with-Patriots-Fest-Music-Festival-Set-for-M?id=438516
$CBDL - The last few months have seen our team transforming everything about our approach to CBD and reimagining our branding and online presence.
https://finance.yahoo.com/news/cbd-life-sciences-provides-exciting-120000086.html
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
$VGLS ON WATCH -- HUGE UPDATE COMING SOON...
$VGLS
— DACE (@DACE0325) April 18, 2024
The natural resources sector remains a cornerstone of the stock market, fueling growth and driving investor interest. From renewable energy to mining, it’s a dynamic landscape where innovation meets opportunity. 🌍💼 #NaturalResources #StockMarket #Investing
The future looks bright for $VGLS! 💼 With a strategic focus on real estate investment, we're poised to seize new opportunities and drive growth.
🚀 The future looks bright for $VGLS! 💼 With a strategic focus on real estate investment, we're poised to seize new opportunities and drive growth. Stay tuned as we embark on this exciting journey towards a prosperous future! 🌟🏢 #VGLS #RealEstate #Growth
— DACE (@DACE0325) April 18, 2024
Trending $ABQQ $FSRN…
$AGBA - The challenges faced in 2023 prompted successful changes to AGBA's business model, resulting in increased focus and efficiency. The implementation of significant cost-cutting measures is expected to reduce normalized operating expenses to a level for strong growth and profitability.
https://www.marketwatch.com/press-release/agba-group-is-positioned-for-hong-kong-s-rebounding-macro-environment-with-business-refinements-and-growth-strategies-f566e8f4
$IQST is heating up, and word is, $1 is within reach when they announce their latest acquisition.
https://www.prnewswire.com/news-releases/iqst--iqstel-q1-record-breaking-revenue-exceeds-50m-not-including-recent-acquisition-302114251.html
$GTVH Lavish Entertainment, Inc. Expands Presence in Event Production Industry Through the Acquisition of ABI Create
https://www.globenewswire.com/news-release/2024/04/11/2861416/0/en/Lavish-Entertainment-Inc-Expands-Presence-in-Event-Production-Industry-Through-the-Acquisition-of-ABI-Create.html
$PDGO - In connection with the previously announced change in control, the new management of PDGO has commenced the process of identifying and initiating targeted acquisitions for PDGO.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241
$NXGB - In its first quarter of operations under the NxGen Brands ownership, Mad House is set to achieve topline revenues of somewhere between $200,000 and $250,000 in first quarter sales.
https://finance.yahoo.com/news/nxgen-brands-inc-releases-bullish-123000349.html
$TREIF Treatment AI Passes Medical School Clinical Exam with 92% Success Rate https://finance.yahoo.com/news/treatment-ai-passes-medical-school-123000812.html
$TREIF Treatment AI Passes Medical School Clinical Exam with 92% Success Rate https://finance.yahoo.com/news/treatment-ai-passes-medical-school-123000812.html
OTC: $TREIF CSE $TRUE NEWS
Treatment.com AI Funded by the National Institute of Health to Develop a Culturally Sensitive AI Approach to Health Equity
$EDXC's low price is chance for us, ain't gonna miss that.
$TWOH is hopeful for a market rebound from its recent downturn and aims to deliver robust returns to investors starting as soon as the overhanging shares from the previous finance partner are exhausted. https://twohandsgroup.com/blog/twoh-weathering-the-storm
$TWOH is hopeful for a market rebound from its recent downturn and aims to deliver robust returns to investors starting as soon as the overhanging shares from the previous finance partner are exhausted. https://twohandsgroup.com/blog/twoh-weathering-the-storm
$IFBC A Ground-Floor Opportunity in a Growing Energy Drink Company #IFBC https://reddit.com/r/PennyStocksWatch/comments/1bk9scq/ifbc_a_groundfloor_opportunity_in_a_growing/
One compelling reason to consider investing in $TWOH is the definitive potential for more strategic acquisitions of small wholesale grocery distributors. https://twohandsgroup.com/blog/twoh-weathering-the-storm
$EDXC - Endexx Corporation Embarks on Strategic Transformation: Leadership Evolution and Intensified Focus on HYLA's Market Dominance
https://finance.yahoo.com/news/endexx-corporation-embarks-strategic-transformation-030020439.html
$EVKRF - To complete the Technical Report, the Company used the results of prior soil samples, geophysical surveys, and drilling on the property, to help identify structure and target areas favorable to lithium accumulation and determine next steps for its overall exploration plan.
$DTMXF - Power Hour buying opportunity.
Branding
Use AnalyticsGPT to discern the values and messages that truly resonate with your audience. A strong, data-driven brand narrative ensures you remain top-of-mind, fostering customer loyalty and repeat business.
https://www.datametrex.com/analyticsgpt
$ARTM News March 05, 2024
American Nortel Communications, Inc. Announces the Availability of its IOS Platform for NewborhoodTalks.com
https://finance.yahoo.com/news/american-nortel-communications-inc-announces-133000601.html
$CYIO - The company is especially excited to be partnering with a tier-1 US carbon offset project that has recently launched as an independently validated and verified project on the American Carbon Registry (ACR).
https://finance.yahoo.com/news/cyios-corp-shareholder-carboncred-carbon-150000460.html
$EDXC recently experienced a downturn due to a missed filing deadline. However, the exciting part is that once they resolve their paperwork issues, there's significant potential for a substantial upward surge. 🌕 This might just be the rebound opportunity we've all been anticipating, so it's crucial to stay alert. Conduct thorough due diligence, but my intuition suggests that this could be a golden chance for gains. 📈💰 Don't overlook this – it's shaping up to be a promising investment prospect! 🚀
https://finance.yahoo.com/news/endexx-corporation-announces-transition-auditor-140000342.html
$SYNX Silynxcom Received $550,000 in Orders from Israel Defense Forces and Israeli Police Forces Since Beginning of Year
https://finance.yahoo.com/news/silynxcom-received-550-000-orders-142800035.html
$RENB - The company has also made progress in advancing its cancer vaccine, RENB-DC11, toward studies in human, based on results obtained in experiments of pancreatic cancer in humanized mice.
https://finance.yahoo.com/news/renovaro-biosciences-releases-ceo-shareholder-143000252.html
$CBDW -- By 2024, 40% of business apps will come with conversational AI as an embedded feature, according to AIM Research.
$CBDW -- By 2024, 40% of business apps will come with conversational AI as an embedded feature, according to AIM Research. https://t.co/BMlZUAMQRV#chatcbdw #cbdwai #1606corp #OpenAI #Azure #AI #Chatbots #growthstrategy #Meta #Microsoft #News #articleoftheday #OTCmarkets pic.twitter.com/5IUitRHNFP
— Stocks On High ALert💯 (@StockOnHighALer) February 22, 2024
$EVKRF: Grid Battery Metals Provides Update for the Proposed Spin-out and TSX Venture listing of its subsidiary, AC/DC Battery Metals Inc.
Click here for news with images:
https://www.caledonianrecord.com/news/national/grid-battery-metals-provides-update-for-the-proposed-spin-out-and-tsx-venture-listing-of/article_c2694793-002c-5417-bf0c-25e1c88a4722.html
$ALST AllStar Health Brands Inc. Acquires Major Interest in Italian Football Club Sanremo; Expands Sports Operations to North America
https://www.accesswire.com/835298/allstar-health-brands-inc-acquires-major-interest-in-italian-football-club-sanremo-expands-sports-operations-to-north-america
CRDV continues to accumulate rental properties in prime locations. The current market landscape is filled with tremendous value propositions and opportunities to continue expanding our portfolio.”— $CRDV CEO Richard Balles
$TMGI The Marquie Group Ventures into the Growing Nootropics Beverage Sector
$TMGI The Marquie Group Ventures into the Growing Nootropics Beverage Sector https://t.co/KKs3I4uyMP
— TMGI (@TheMarquieGroup) February 20, 2024
$NICH - Welcome to Nitches, where we don’t just anticipate the future, we create it. Our vision aligns with industry giants like JP Morgan and Blackrock, embracing the verification, tokenization and digital transformation sweeping across industries. https://nitchescorp.com/
$RENB - Cyclomics has already developed an early detection technology called “CyclomicsSeq TP53”, an in vitro diagnostic (IVD) kit integrating an innovative sequencing methodology and state-of-the-art analysis software.
https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-142500523.html
$RONN is an automotive company at the forefront of hydrogen fuel cell technology. Recognized for its unique propulsion solutions, RONN is committed to delivering high-performance vehicles and hydrogen production systems that prioritize environmental responsibility and efficiency. www.ronnmotorgroup.com
Nitches (OTCPink: $NICH) Unveils Exciting Flavor Profiles for 2024 https://finance.yahoo.com/news/nitches-otcpink-nich-unveils-exciting-142000348.html
$CRDV - MISSION
We are a publicly traded real estate growth company focused on providing affordable housing solutions for low to moderate income households.
https://www.communityredevelopment.net/about
$EVKRF: Blue Skies Ahead for EVs and the Energy Metals That Power Them
Blue Skies Ahead for EVs and the Energy Metals That Power Them
— Grid Battery Metals Inc (@GRIDBattery) February 20, 2024
Click on the link to read the full article.https://t.co/WRMLsaIiFs$CELL $EVKRF #Lithium #ElectricVehicles #BatteryMetals #Nevada
1606 Corp. $CBDW Signs Strategic Partnership With Flex Payment Solutions & ChatCBDW AI https://www.reddit.com/r/Shortsqueeze/comments/1avj9f2/1606_corp_cbdw_signs_strategic_partnership_with/
$RENB - GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.
https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-144600061.html
$BNNHF Benjamin Hill $BNN appoints Russell Ball, former EVP and CFO of
@NewmontCorp
and Goldcorp, as Senior Advisor. With over 30 years of experience, Russell is ready to help advance our projects, including the exciting La Estrella project in Colombia.
Starting next week, $CBDW & Cool Blue will begin a BRAND NEW marketing campaign focused entirely on CBD Brands!
$CBDW Corporate Update!
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) February 9, 2024
Starting next week, CBDW & Cool Blue will begin a BRAND NEW marketing campaign focused entirely on CBD Brands!
After phenomenal results from our merchant centered campaign in Dec, we're doubling down & launching MC 2.0.
Stay tuned, more details later… pic.twitter.com/OLEaNMEUmL
$CBDW Corporate Update!
$CBDW Corporate Update!
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) February 9, 2024
Starting next week, CBDW & Cool Blue will begin a BRAND NEW marketing campaign focused entirely on CBD Brands!
After phenomenal results from our merchant centered campaign in Dec, we're doubling down & launching MC 2.0.
Stay tuned, more details later… pic.twitter.com/OLEaNMEUmL
$CBDW - Despite Corporate Cost-Cutting, CEOs Are All In On Investing In Generative AI https://cbdw.ai/despite-corporate-cost-cutting-ceos-are-all-in-on-investing-in-generative-ai/
$AVRW is set for a high growth sales and revenue year in 2024 based on all the positive groundwork that has been laid to date. The company's Seratopoical Revolution brand has clearly been demonstrated as top quality in terms of its formulations and performance, especially with the very high level endorsements that have been presented.
$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter
From this article:
– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.
– Company Currently Holds 15 Patents.
– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.
– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.
– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.
– Q3 Net Revenue Increased Sequentially from Q2 2023.
– Sales Expected to Increase Significantly During Q4 and Into 2024.
– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.
– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.
– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns
In the exclusive interview, Lambrecht discussed the innovative AI merchandising bot developed by $CBDW 1606 Corp., specifically designed for the CBD industry. https://www.redchip.com/assets/access/cbdw_access
Followers
|
625
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
38186
|
Created
|
05/31/10
|
Type
|
Free
|
Moderator stockseekerok | |||
Assistants TPX |
OTC MARKET PLAYS
Here We Will Follow The Hot Stocks Of The Day
Any Stock That is Moving Positively Will be A hot Stock Of The Day
Here we Dedicate to Low Float Stocks Becuase when they Move they provide the Largest Gains
We Strive To Locate any Stock That is Moving intraday.
We like to see a level 2 setup that shows that the Intraday Play has potential to provide a large move
Join Us And Play The Hot Stocks Of The Day
Investors Just do Not Realize That When A stock Is at its Lowest Share Structure Is when the Most Money Can Be Made.
Yes The Lack Of Volume and Trading History Concerns you.
Why Is there a lack Of Volume ?
Because Investors will not get together and see that If Many buy the stock and create the momentum that the rest of IHUB will join Right In.
A Stock that is not Promoted and Has a Low Share Structure will Rise with Volume.
If you Want to Make Money Then Sign Up For The Alerts In The Sticky Posts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |